NCT06181994

Brief Summary

This multi-center retrospective cohort study aims to investigate the real-world outcomes of chronic subdural hematoma treated with MMAE, including clinical effectiveness, recurrence rates, and safety profile.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5,000

participants targeted

Target at P75+ for all trials

Timeline
3mo left

Started Dec 2023

Typical duration for all trials

Geographic Reach
3 countries

19 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress91%
Dec 2023Aug 2026

First Submitted

Initial submission to the registry

December 5, 2023

Completed
Same day until next milestone

Study Start

First participant enrolled

December 5, 2023

Completed
21 days until next milestone

First Posted

Study publicly available on registry

December 26, 2023

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2026

Last Updated

January 7, 2026

Status Verified

January 1, 2026

Enrollment Period

2.7 years

First QC Date

December 5, 2023

Last Update Submit

January 5, 2026

Conditions

Keywords

Middle meningeal artery embolizationEndovascular Embolization

Outcome Measures

Primary Outcomes (2)

  • Reaccumulation of Hematoma

    The percentage of patients who were determined to have a reaccumulation of their hematoma will be tabulated and reported

    Within 1 month post MMAE

  • Rescue surgical evacuation

    The percentage of patients who were determined to require rescue surgical evacuation of their hematoma will be tabulated and reported

    Between 1-3 months post MMAE

Secondary Outcomes (17)

  • Reaccumulation of Hematoma

    Between 1-3 months post MMAE

  • Reaccumulation of Hematoma

    Between 3-6 months post MMAE

  • Reaccumulation of Hematoma

    Between 6-12 months post MMAE

  • Reaccumulation of Hematoma

    Between 12-24 months post MMAE

  • Clinical Outcome at Follow-up Clinical outcome at follow-up

    Upon study discharge, 1-4 weeks

  • +12 more secondary outcomes

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with chronic subdural hematoma

You may qualify if:

  • Consecutive adult patients (18 yrs. of age or older)
  • Endovascular embolization of middle meningeal artery using any embolization material:
  • PVA particles; Onyx, nBCA glue; dimethyl sulfoxide, microcoils, PVA with microcoils

You may not qualify if:

  • Endovascular embolization of middle meningeal artery using any other embolization material

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (19)

Baptist Health South Florida, Inc.

Coral Gables, Florida, 33143, United States

RECRUITING

Mayo Clinic Florida

Jacksonville, Florida, 32224, United States

COMPLETED

Orlando Regional Medical Center

Orlando, Florida, 32806, United States

RECRUITING

University of Illinois Chicago

Chicago, Illinois, 60607, United States

COMPLETED

University of Chicago Medicine

Chicago, Illinois, 60637, United States

RECRUITING

The University of Iowa

Iowa City, Iowa, 52242, United States

COMPLETED

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

RECRUITING

Beth Israel Deaconess Medical Center (BIDMC)/Harvard Medical School

Boston, Massachusetts, 02215, United States

RECRUITING

Lahey Hospital and Medical Center

Burlington, Massachusetts, 01805, United States

RECRUITING

Mayo Clinic

Rochester, Minnesota, 55905, United States

COMPLETED

Montefiore Medical Center

The Bronx, New York, 10467, United States

RECRUITING

Geisinger Health

Danville, Pennsylvania, 17822, United States

COMPLETED

Thomas Jefferson University

Philadelphia, Pennsylvania, 19144, United States

RECRUITING

UTHealth Houston

Houston, Texas, 77030, United States

COMPLETED

HCA Houston Healthcare Kingwood

Kingwood, Texas, 77339, United States

COMPLETED

Austin Health

Heidelberg, Victoria, 3084, Australia

RECRUITING

Unity Health Toronto

Toronto, Ontario, M5C 2T2, Canada

COMPLETED

University of Toronto

Toronto, Ontario, M5S 1A1, Canada

RECRUITING

Toronto Western Hospital

Toronto, Ontario, M5T 2S8, Canada

COMPLETED

MeSH Terms

Conditions

Hematoma, Subdural, Chronic

Condition Hierarchy (Ancestors)

Hematoma, SubduralIntracranial Hemorrhage, TraumaticIntracranial HemorrhagesCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesCraniocerebral TraumaTrauma, Nervous SystemVascular DiseasesCardiovascular DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsHematomaHemorrhageWounds and Injuries

Study Officials

  • David Altschul, MD

    Montefiore Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Muhammed Amir Essibayi, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 5, 2023

First Posted

December 26, 2023

Study Start

December 5, 2023

Primary Completion (Estimated)

August 1, 2026

Study Completion (Estimated)

August 1, 2026

Last Updated

January 7, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will not share

Locations